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a b s t r a c t
The datasets presented in this article are related to the research
articles entitled “Neutrophil Extracellular Traps in Ulcerative Colitis:
A Proteome Analysis of Intestinal Biopsies” (Bennike et al., 2015 [1]),
and “Proteome Analysis of Rheumatoid Arthritis Gut Mucosa”
(Bennike et al., 2017 [2]). The colon mucosa represents the main
interacting surface of the gut microbiota and the immune system.
Studies have found an altered composition of the gut microbiota in
rheumatoid arthritis patients (Zhang et al., 2015; Vaahtovuo et al.,
2008; Hazenberg et al., 1992) [5–7] and inﬂammatory bowel disease
patients (Morgan et al., 2012; Abraham and Medzhitov, 2011;
Bennike, 2014) [8–10]. Therefore, we characterized the proteome of
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Neutrophil extracellular traps
Dataset
Sigmoidoscopy
Colonoscopy
colon mucosa biopsies from 10 inﬂammatory bowel disease ulcera-
tive colitis (UC) patients, 11 gastrointestinal healthy rheumatoid
arthritis (RA) patients, and 10 controls. We conducted the sample
preparation and liquid chromatography mass spectrometry (LC-MS/
MS) analysis of all samples in one batch, enabling label-free com-
parison between all biopsies. The datasets are made publicly avail-
able to enable critical or extended analyses. The proteomics data and
search results, have been deposited to the ProteomeXchange Con-
sortium via the PRIDE partner repository with the dataset identiﬁers
PXD001608 for ulcerative colitis and control samples, and
PXD003082 for rheumatoid arthritis samples.
& 2017 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Speciﬁcations Table
Subject area Biology
More speciﬁc sub-
ject area
Characterization of the proteome of the colon mucosa of ulcerative colitis
patients, gastrointestinal healthy rheumatoid arthritis patients, and controls.
Type of data Raw- mass spectrometry ﬁles and text/excel ﬁles
How data was
acquired
Mass Spectrometry Liquid Chromatography
Data was acquired using a high-resolution/high-accuracy Q Exactive plus
(Thermo Scientiﬁc) mass spectrometer.
Data format Raw- and analyzed data.
Experimental
factors
Human colon mucosal biopsies from ulcerative colitis patients, gastrointestinal
healthy rheumatoid arthritis patients, and controls.
Experimental
features
Biopsies were extracted by colonoscopy and immediately snap-frozen with
liquid nitrogen. The biopsies were tryptic digested and analyzed by electrospray
ionization liquid chromatography mass spectrometry.
Data source
location
The Laboratory for Medical Mass Spectrometry, Department of Health Science
and Technology, Aalborg University, Fredrik Bajers Vej 7E, 9220 Aalborg East,
Denmark
Data accessibility The proteomics data have been deposited to the ProteomeXchange Con-
sortium via the PRIDE partner repository, [13–16] with dataset identiﬁers:
PXD001608 – Ulcerative colitis patients, and controls.
PXD003082 – Gastrointestinal healthy rheumatoid arthritis patients.
Direct download links: http://www.ebi.ac.uk/pride/archive/projects/
PXD001608
http://www.ebi.ac.uk/pride/archive/projects/PXD003082
Value of the data
 The dataset contains the largest number of identiﬁed human proteins from colon mucosa biopsies
as of 2017.
 The dataset was obtained in one batch, allowing for label-free comparison of the colon mucosa of
ulcerative colitis patients, rheumatoid arthritis patients, and controls.
 The ﬁrst dataset of the colon mucosa of gastrointestinal healthy RA patients.
 The datasets can be analyzed for novel proteome effects of disease and treatments.
 The datasets allow for extended statistical analysis, and we encourage such collaborations.
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1. Data
The datasets in this article provides information on the proteome of the colon mucosa of inﬂammatory
bowel disease patients with ulcerative colitis [1], gastrointestinal healthy rheumatoid arthritis patients [2],
and controls. The study was motivated by the ﬁnding of an altered composition of the gut microbiota in
rheumatoid arthritis patients [5–7] and inﬂammatory bowel disease patients [8–10]. All biopsies were
handled on-site by the project group to limit technical variance. The biopsies were randomized, digested
using a modiﬁed ﬁlter-aided sample preparation protein digestion protocol, and analyzed in technical tri-
plicates by high-throughput proteomics on a Q Exactive mass spectrometer. All experimental factors were
kept constant, allowing for a label-free quantitative analysis between all samples. The unprocessed pro-
teomics data ﬁles (Table 1) and processed search result ﬁles (Table 2), have been deposited to the Pro-
teomeXchange Consortium via the PRIDE partner repository, with the dataset identiﬁer PXD001608 for
ulcerative colitis and control samples, and PXD003082 for rheumatoid arthritis samples [13,14].
A cumulated 6768 proteins (FDRo1%) were identiﬁed, representing the largest proteome dataset
of the colon mucosa so far. Additionally, the dataset represents the ﬁrst analysis of the colon mucosa
of gastrointestinal healthy rheumatoid arthritis patients. The data-analysis result from the analysis
Table 1
Raw-dataﬁles in PXD001608 and PXD003082. All samples were analyzed in technical triplicates, and all raw-ﬁles are named
accordingly (e.g. Ctrl_10_3 is the third repeat of control 10). “Poor R” signiﬁes a Pearson's correlation coefﬁcient Ro0.95
between the technical repeats, and additional data validation is recommended for studies including these dataﬁles. The
number of identiﬁed proteins in each replicate is given, wo/w the MaxQuantmatch between runs feature which transfer MS/MS
information between different LC-MS/MS analysis. RA: Rheumatoid arthritis, UC: ulcerative colitis, NA: Not available.
Filename Sample #Proteins matching OFF #Proteins matching ON Dataset ID Comment
Ctrl_1 Control 4362, 4279, 4241 5967, 5903, 5897 PXD001608
Ctrl_2 Control 3613, 3607, 3595 5657, 5664, 5723 PXD001608
Ctrl_3 Control 4203, 4203, 4188 5936, 5952, 5939 PXD001608
Ctrl_4 Control 4245, 4268, 4191 5863, 5865, 5849 PXD001608
Ctrl_5 Control 3961, 3881, 3903 5694, 5683, 5632 PXD001608
Ctrl_6 Control 4290, 4281, 4242 5966, 5959, 5932 PXD001608
Ctrl_7 Control 4080, 4099, 4097 5856, 5822, 5817 PXD001608
Ctrl_8 Control 4269, 4325, 4336 5968, 5986, 5966 PXD001608
Ctrl_9 Control 4560, 4549, 3974 6103, 6126, 6103 PXD001608
Ctrl_10 Control 3974, 3993, 3972 5781, 5817, 5779 PXD001608
UC_1 UC 4290, 4229, 4363 5870, 5852, 5907 PXD001608
UC_2 UC 3328, 3285, 3328 5148, 5101, 5139 PXD001608
UC_3 UC 4455, 4472, 4482 6068, 6082, 6041 PXD001608
UC_4 UC 4236, 4005, NA 5685, 5773, NA PXD001608 UC_4_3 poor R
UC_5 UC 3097, 3174, NA 5051, 5017, NA PXD001608 UC_5_3 poor R
UC_6 UC 4458, 4424, 4482 6118, 6108, 6115 PXD001608
UC_7 UC 3657, 3686, 3693 5647, 5626, 5575 PXD001608
UC_8 UC 3356, 3288, 3303 5237, 5207, 5164 PXD001608
UC_9 UC 4681, 4700, 4703 6220, 6233, 6223 PXD001608
UC_10 UC 3762, 3688, 3674 5587, 5557, 5562 PXD001608
RA_1 RA 3900, 3789, 3755 5658, 5644, 5632 PXD003082
RA_2 RA 4347, 4141, 4285 6023, 5997, 5973 PXD003082
RA_3 RA 4654, 4678, 4629 6204, 6179, 6180 PXD003082
RA_4 RA 4298, 4287, 4267 5933, 5925, 5899 PXD003082
RA_5 RA 3472, 3521, 3491 5402, 5390, 5344 PXD003082
RA_6 RA 3545, 3485, 3526 5735, 5742, 5728 PXD003082
RA_7 RA 4538, 4476, 4459 6057, 6062, 6071 PXD003082
RA_8 RA 3619, 3439 NA 5317, 5310, NA PXD003082 RA_8_3 poor R
RA_9 RA 3361, NA, 3427, 5256, NA, 5187 PXD003082 RA_9_2 poor R
RA_10 RA 4417, 4354, 4361 5991, 6010, 6023 PXD003082
RA_11 RA 3094, 3055, 3051 5005, 5050, 5006 PXD003082
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with MaxQuant can be downloaded as zipped txt-ﬁles, the context of which are described in the
tables.pdf also in the zipped ﬁle. The result-ﬁle proteinGroups.txt, contains all identiﬁed proteins at
o1% FDR, and information regarding each protein, e.g. the corresponding label-free relative quan-
titation value (LFQ). Additional information regarding the participants can be found in the
publications.
2. Experimental design, materials and methods
2.1. Study cohort and sample collection
The sample material was extracted and processed as described in [1] and 2].
Colon mucosal biopsies (roughly 1 mm3) were sampled 40 cm from the anus by sigmoidoscopy, at
the Regional Hospital Silkeborg Denmark, from 10 ulcerative colitis patients, 11 rheumatoid arthritis
patients and 10 controls in the period from 2012 to 2013. The biopsies were immediately transferred
to cryotubes and snap-frozen in liquid nitrogen followed by storage at minus 80 °C until proteomics
sample preparation. All participants had given a written informed consent prior to participation in
the study, and the project was approved by The Regional Scientiﬁc Ethical Committee (S-20120204)
and the Danish Data Protection Agency (2008-58-035).
2.2. Proteomic sample preparation
The biopsies were randomized, and enzymatic digested using a modiﬁed ﬁlter-aided sample
preparation protein [17–22]. Brieﬂy explained, the biopsies were homogenized in 0.5 mL cold sample
buffer (5% sodium deoxycholate, 50 mM triethylammonium bicarbonate, pH 8.5). The lysate protein
concentration was estimated by absorbance at 280 nm measured using a NanoDrop 1000 UV–vis
spectrophotometer (Thermo Scientiﬁc, Waltham, MA, USA). Additionally, the concentration of four
biopsy lysates was determined using a bicinchoninic acid assay (BCA) with bovine serum albumin as
standard, measured using an Inﬁnite microplate reader (Tecan, Männedorf, Switzerland). The nano-
drop measurements were calibrated using the BCA results. 100 µg protein was transferred to 30 kDa
molecular weight cutoff spin-ﬁlters (Millipore, Billerica, MA, USA) to facilitate buffer exchanges by
centrifugation at 15,000g for 15 min between all steps. Protein disulﬁde bonds were reduced by
addition of 100 µL 10 mM tris(2-carboxyethyl)phosphine (Thermo Scientiﬁc, Waltham, MA, USA) and
alkylated by addition of 100 µL 50 mM 2-iodoacetamide (Sigma-Aldrich, St. Louis, MO, USA) in sample
buffer. Two µg sequencing grade modiﬁed trypsin (Promega, Madison, WI, USA) diluted in lysis buffer
with 0.5% sodium deoxycholate was added to the spin-ﬁlter, and the proteins were digested to
peptides overnight at 37 °C. The peptide material was eluted from the spin-ﬁlter and puriﬁed by
phase inversions with 1:1 (v/v) ethyl acetate with 1% formic acid, and dried down in a vacuum
centrifuge overnight, and stored at −80 °C for a maximum of one week prior to analysis.
Table 2
Additional submitted Search and FASTA ﬁles in PXD001608 and PXD003082. RA: Rheumatoid arthritis, UC: ulcerative colitis.
Filename Dataset ID Content Description
CombinedTxtFiles.zip PXD001608 Zipped Max-
Quant combined
txt folder.
Result of the label-free quantitative analysis of UC and
controls in MaxQuant. The content of each ﬁle is
described in “tables.pdf”.
131008_Swissprot_Human_Ref_
proteome.fasta
PXD001608 Protein FASTA
database ﬁle.
Protein database used for the UC and controls analysis.
MaxQuantOutput.zip PXD003082 Zipped Max-
Quant combined
txt folder.
Result of the label-free quantitative analysis of UC, RA,
and controls in MaxQuant. The content of each ﬁle is
described in “tables.pdf”.
UniprotHumanProteome
P000005640Isoforms.fasta
PXD003082 Protein FASTA
database ﬁle.
Protein database used for the UC, RA, and controls
analysis.
FASTA ﬁle parameters.txt PXD003082 FASTA info. Information regarding the database.
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2.3. Proteomic analysis
The peptides were analyzed by LC-MS/MS using an UltiMate 3000 UPLC system (Thermo Scientiﬁc,
Waltham, MA, USA) coupled online to a Q Exactive plus mass spectrometer (Thermo Scientiﬁc). Five
µg peptide material was loaded onto a 2 cm reverse phase C18-material trapping column and sepa-
rated on a 50 cm analytical column, both from Acclaim PepMap100 (Thermo Scientiﬁc). The liquid
phase consisted of 96% solvent A (0.1% formic acid) and 4% solvent B (0.1% formic acid in acetonitrile),
at a ﬂow rate of 300 nL/min. The peptides were eluted from the column by increasing to 8% solvent B
and subsequently to 30% solvent B on a 225 min ramp gradient, and introduced into the mass
spectrometer by a picotip emitter for electrospray ionization (New objective, Woburn, MA, USA). The
mass spectrometer was operated in positive mode with data-dependent acquisition, alternating
between survey spectra and isolation/fragmentation spectra using a top12 method. Selected eluting
peptides were excluded from re-analysis for 30 s. All biopsies were analyzed in triplicates in a random
order.
2.4. Data processing
The generated RAW-ﬁles were searched with MaxQuant 1.5.2.8 software against the Uniprot
Homo sapiens reference proteome database with isoforms (UP000005640, last modiﬁed 2015-01-16,
entry count 90,434) [23,24]. Standard settings were employed, with the following abundant peptide
modiﬁcations included in the search: Carbamidomethylated(C) (ﬁxed), N-terminal protein acetylation
(variable), oxidation(M) (variable), and deamidation (N or Q) (variable) [11,12]. The match between
runs feature in MaxQuant was enabled to allow the transfer of conﬁdent peptides identiﬁcations
across LC-MS/MS runs, based on accurate mass-to-charge and retention time. Identiﬁed proteins and
peptides were ﬁltered to o1% false discovery rate [25]. Label-free quantitation was enabled in
MaxQuant to report protein and peptide relative quantities using standard parameters.
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